The regulator that put generative AI in front of its own reviewers is also the one drawing the hardest line about what AI is not allowed to decide.
Short answer: The FDA has stated that its AI tools do not make regulatory decisions or replace human judgement, and its April 2026 warning letter on AI in drug manufacturing reinforced that AI-generated outputs must be reviewed and approved by authorised Quality Unit personnel.
Key takeaways
- The FDA has stated that AI tools do not make regulatory decisions or replace human judgement. In April 2026 the agency issued a warning letter highlighting the risks of using AI in drug.
- 133 live listings in this category publish a rate, at a median top-of-range of $67 an hour and a ceiling of $230.
- The work is remote contract work, asynchronous, with no set hours and no guaranteed volume.
- Applications screen on a short skills assessment rather than a resume or interview.
What was reported
The finding
The FDA has stated that AI tools do not make regulatory decisions or replace human judgement. In April 2026 the agency issued a warning letter highlighting the risks of using AI in drug manufacturing, cautioning that AI-generated outputs must undergo review and approval by authorised Quality Unit personnel, and reinforcing that a human in the loop remains the norm and expectation for functions impacting product quality or patient safety. This sits alongside the ten Guiding Principles of Good AI Practice in Drug Development that the FDA and EMA published jointly in January 2026, which emphasise that AI should support rather than replace human regulatory and clinical decision-making, with investigator oversight responsibilities around safety assessments remaining fundamentally human.
The FDA's position is stated plainly: AI tools do not make regulatory decisions or replace human judgement. In April 2026 it backed that with enforcement, warning that AI-generated outputs in drug manufacturing must be reviewed and approved by authorised Quality Unit personnel, and that a human in the loop remains the expectation wherever product quality or patient safety is affected.
What the listings pay
That is not a temporary position pending better models. It is the same principle running through the ten guiding principles the FDA and EMA published jointly in January, and through the FDA's own reviewers reporting inaccuracies in the Elsa tool it deployed agency-wide.
| # | Role | Advertised rate | Platform |
|---|---|---|---|
| 1 | Disease-Area Clinician, Trial Endpoints & Prescribing | $150 to $230 an hour | Mercor |
| 2 | Pharma Commercial Forecasting Expert, Launch Curves | $130 to $210 an hour | Mercor |
| 3 | Therapeutic Area & Clinical Survey Expert | $200 to $200 an hour | Mercor |
| 4 | Clinician (Oncology / Hematology) | $160 to $200 an hour | micro1 |
| 5 | Multilingual Primary Care Physician (MD): Clinical Documentation & AI Evaluation | $170 to $190 an hour | Mercor |
| 6 | Medical Safety Expert | $140 to $190 an hour | Mercor |
| 7 | Clinical Law Professor / Clinic Director | $180 to $180 an hour | Mercor |
| 8 | Multilingual Inpatient Hospitalist (MD): Clinical Documentation & AI Evaluation | $170 to $170 an hour | Mercor |
| 9 | Clinical Regulatory Expert | $130 to $170 an hour | Mercor |
| 10 | Pharmacologist | $120 to $170 an hour | Mercor |
Source: 133 live listings on this board that publish a rate, read directly from each posting on 2026-09-06. Listings without a published rate are excluded rather than estimated.
How this compares across the board
A rate only means something next to the alternatives. This is every category we track with at least five listings publishing a rate, ranked by median top-of-range, so you can see where this work sits rather than taking a single number on trust.
| Category | Listings | Median low | Median top | Highest |
|---|---|---|---|---|
| Legal | 95 | $100 | $140 | $400 |
| Medical | 68 | $77 | $120 | $400 |
| Consulting | 45 | $80 | $120 | $280 |
| Finance | 94 | $80 | $110 | $280 |
| Engineering | 114 | $70 | $100 | $300 |
| Research/PhD | 132 | $70 | $90 | $280 |
| Writing | 36 | $40 | $80 | $280 |
| Bilingual | 78 | $44 | $52 | $120 |
| Annotation | 25 | $12 | $24 | $120 |
Same source and date as above. Categories are matched on listing title, so a role can appear in more than one.
What it means for you
The practical consequence is a durable requirement for qualified people to review AI output and be accountable for the review. Across 133 live regulatory, clinical and quality listings on our board that publish a rate, the median top-of-range is $67 an hour, reaching $230.
What an enforcement action changes
Guidance describes what regulators would prefer. A warning letter describes what they will act on, which is why the April 2026 letter matters more than the volume of AI guidance published around it.
The specific requirement is documentary: AI-generated output has to be reviewed and approved by a named, authorised person in the Quality Unit. That converts a vague expectation of oversight into an auditable step with a person attached to it.
For anyone in regulatory, quality or manufacturing, this is the useful read. The compliance burden is not on the tool, it is on demonstrating that a competent human evaluated what the tool produced.
Why labs buy this same expertise
A model that produces a fluent, well-structured, subtly wrong regulatory document is exactly the failure the FDA is legislating against. Labs know this, and the people who can spot it are the ones who have written or reviewed the real thing.
Regulatory affairs, quality, pharmacovigilance and clinical development backgrounds all map directly. The scarce skill is knowing what an inspector asks and being able to answer it in writing.
As with all clinical listings on this board, there is no patient contact and no protected health information involved, so it sits outside the constraints that apply to practice.
Who should apply
Two checks before you spend time on an application. Confirm the role accepts applicants from your country with the eligibility checker, since a meaningful share of listings carry location requirements. Then run the advertised rate through the take-home calculator, because this is contract work and the headline figure is before self-employment tax.
Applications complete on the hiring platform and usually take a few minutes, with a short skills assessment in place of an interview. Fill in every credential, language and professional background field on your profile. Those are what route you to the better paid listings, and most applicants leave them blank.
Frequently asked questions
What is the FDA's position on AI?
The agency has stated that AI tools do not make regulatory decisions or replace human judgement, a position reinforced by its April 2026 warning letter and the joint FDA/EMA guiding principles.
What did the April 2026 warning letter say?
It highlighted risks of using AI in drug manufacturing and cautioned that AI-generated outputs must undergo review and approval by authorised Quality Unit personnel.
Does the FDA use AI itself?
Yes. It deployed its Elsa tool agency-wide, while its own reviewers have reported responses containing inaccuracies or incomplete data.
Is this position likely to change?
It runs through the joint FDA and EMA principles as well as enforcement, both framed around human-centric, risk-based oversight rather than a temporary limitation.
What does regulatory AI work pay?
Across 133 live regulatory, clinical and quality listings publishing a rate, the median top-of-range is $67 an hour, reaching $230.
What backgrounds fit these roles?
Regulatory affairs, quality, pharmacovigilance and clinical development. Knowing what an inspector will ask is the specific value.
Is PHI involved?
No. You evaluate model output using your regulatory and clinical knowledge, with no patient contact and no protected health information.
Sources
See every live role
The full board updates several times a week, with the advertised rate on each listing and closed roles removed.